ARIAD prescription drugs, Inc. could be a biopharmaceutical
company, focuses on the invention, development, and development of
small-molecule medication for the treatment of cancer. The corporation has 3
products: Ridaforolimus, Ponatinib and AP26113. Its strategy to structure-based
drug style has a light-emitting diode to a few internal fund, molecularly
targeted product applicants for drug-resistant and difficult-to-treat cancers,
as well as sure styles of chronic chronic leukemia, soft tissue and bone
sarcomas and non-small cell carcinoma. The corporation was based by Harvey J.
Berger in Gregorian calendar month 1991 and is headquartered in Cambridge, MA.
Buy
the rumor, sell the news is fully result these days for Ariad prescription
drugs (NASDAQ: ARIA ) that fell the
maximum amount as 2 hundredth, once saying that the Food and Drug
Administration has approved Iclusig (formerly ponatinib) for the treatment of a
rare blood borne and bone marrow cancer ... with a catch. The once-daily drug
will currently be wanting to treat chronic chronic leukemia, or CML, and city
body positive acute lymphocytic leukemia. Each diseases square measure rare,
that granted Iclusig orphan drug and accelerated review standing. However, the
agency additionally requires a warning on the box for physicians and patients
that Iclusig will cause blood clots and liver toxicity.
Congratulations
are definitely in order for Ariad, that brings its initial FDA-approved drug to
plug, although, as we will see from today's commercialism, only a few investors
expected a warning to be placed on the box. Whereas I welcome any new medication
that improve the healthcare landscape, I am unable to facilitate however be
discouraged regarding its near-term perspective, considering that Ariad, even
with today's drop, continues to be valued at around 3 times peak sales of
Iclusig.
